

Yukon Immunization Program Manual

Section 8 — Biological Products

Polio Vaccine

May 2026



Table of Contents

Polio Vaccine (Inactivated Poliovirus Vaccine, IPV) Imovax Polio®	1
---	---

Polio Vaccine (Inactivated Poliovirus Vaccine, IPV)			Imovax Polio®
Manufacturer	Sanofi Pasteur	Biological Classification	Inactivated viral vaccine
Current Formulation	Contains inactivated poliovirus types 1 (Mahoney), 2 (MEF1), and 3 (Saukett)		
INDICATIONS	Recommended and provided free to:		
	• Infants and children following routine immunization schedule • Children and adults with incomplete, unknown, or OPV only polio immunization history • Solid organ or islet cell transplant candidates or recipients with incomplete or unknown polio immunization history • Household or close contacts of individuals recently vaccinated with oral polio vaccine in countries where OPV is used		
	Recommended but not publicly funded:		
	A single lifetime IPV booster dose may be considered for adults with a documented complete primary series who are at increased risk of exposure to poliovirus, including: • travelers to areas with circulating poliovirus • laboratory workers handling poliovirus specimens • health care workers with potential occupational exposure in higher risk settings • individuals deployed for humanitarian or military work in areas with circulating poliovirus • individuals working directly with populations arriving from areas with circulating poliovirus Adults with a documented complete primary polio immunization series do not require additional IPV doses unless they are at increased risk of exposure. Booster doses for exposure risk are not publicly funded.		
	PUBLICLY FUNDED SCHEDULE		
	Routine pediatric schedule IPV protection for infants and children is normally provided through combination vaccines (DTaP-IPV-Hib or Tdap-IPV). IPV-only vaccine is used when a combination vaccine is not indicated or not available.		

Polio Vaccine (Inactivated Poliovirus Vaccine, IPV)		Imovax Polio®
	1. Children <4 years of age	- Dose 1: 0.5 mL SC - Dose 2: ≥ 8 weeks after Dose 1 - Dose 3: ≥ 12 months after Dose 2 - Booster: at ≥4 years of age AND at least 12 months after Dose 3 Booster is not required if Dose 3 was administered on or after the 4th birthday
	2. Children 4 to 17 years of age	- Dose 1: 0.5 mL SC - Dose 2: ≥ 8 weeks after Dose 1 - Dose 3: ≥ 12 months after Dose 2
	3. Adults ≥18 years of age with unknown, incomplete, or OPV-only polio immunization history	Provide IPV to complete a 3-dose primary series. Do not restart the series regardless of interval since the last dose. - Dose 1: 0.5 mL SC - Dose 2: 0.5 mL SC, ≥ 8 weeks after Dose 1 - Dose 3: 0.5 mL SC, ≥ 12 months after Dose 2
MINIMUM AGE/ INTERVAL	- Minimum Age: - Dose 1: 6 weeks - Booster dose if required: 4 years - Minimum Intervals: Follow recommended intervals whenever possible. Minimum intervals apply when accelerated schedules are required. See Section 3: Immunization Schedules. - Dose 1 to Dose 2: 4 weeks - Dose 2 to Dose 3: 6 months - Dose 3 to booster dose: 6 months	
AVAILABLE FORMAT	- Single-dose pre-filled syringe, 0.5 mL - Ten-dose package (10 × 0.5 mL)	

Polio Vaccine (Inactivated Poliovirus Vaccine, IPV)		Imovax Polio®
CONTRAINDICATIONS	- History of anaphylaxis after a previous dose of an IPV containing vaccine - Immediate or anaphylactic hypersensitivity to any component of the vaccine or its container, including latex	
PRECAUTIONS & SPECIAL CONSIDERATIONS	- Postpone vaccination in persons with moderate or severe acute illness - Minor illness, with or without fever, is not a contraindication to vaccination - Immunocompromised individuals may have a reduced immune response - Hospitalized premature infants should have continuous cardiac and respiratory monitoring for 48 hours after their first immunization OPV history: OPV doses administered on or after April 1, 2016 are not considered valid for completion of the Yukon routine polio immunization schedule. Replace these doses with IPV-containing vaccine to ensure protection against all three poliovirus types and completion of the primary series.	
PREGNANCY AND LACTATION	- IPV containing vaccine may be administered during pregnancy when protection is required and exposure risk is increased - Breastfeeding is not a contraindication to vaccination	
INTERCHANGEABILITY	- Select IPV-containing vaccine based on age, antigen requirements, and publicly funded indications - Use IPV-only vaccine when only polio protection is required	
RECONSTITUTION AND DILUTION	Not required.	
ADMINISTRATION	Dose: 0.5 mL Route: Subcutaneous Preferred site: - Infants and small children: anterolateral thigh - Older children and adults: deltoid or triceps area	

Polio Vaccine (Inactivated Poliovirus Vaccine, IPV)		Imovax Polio®
CONCURRENT ADMINISTRATION WITH OTHER VACCINES	May be administered concurrently with other vaccines at separate injection sites using separate syringes	
SEROLOGICAL TESTING	Not recommended	
VACCINE COMPONENTS	Active ingredients (per 0.5 mL dose): - Poliovirus Type 1 (Mahoney), formaldehyde-inactivated – 29 D-antigen units - Poliovirus Type 2 (MEF1), formaldehyde-inactivated – 7 D-antigen units - Poliovirus Type 3 (Saukett), formaldehyde-inactivated – 26 D-antigen units Non-medicinal ingredients: 2-phenoxyethanol - Trace amounts of formaldehyde - Residual calf serum protein (<1 ppm) - Trace neomycin, streptomycin, polymyxin B	
APPEARANCE	- Clear, colourless suspension - Do not use if cloudy or if particulate matter is present	
BLOOD/ BLOOD PRODUCTS	None	
BOVINE/ PORCINE PRODUCTS	- Residual calf serum protein from the manufacturing process may be present - No components of porcine	
LATEX	Syringe stopper does not contain latex	
EXPECTED REACTIONS	Local: Pain, redness, swelling Systemic: Mild fever, irritability, malaise - Serious adverse events are rare	

Polio Vaccine (Inactivated Poliovirus Vaccine, IPV)		Imovax Polio®
STORAGE AND HANDLING	Storage:	
	• Store at +2°C to +8°C • Do not freeze • Protect from light	
	Handling	
	• Shake well before use • Inspect for particulate matter or discoloration; Do not use if it has a cloudy appearance	
REFERENCES AND RESOURCES		
National Advisory Committee on Immunization Statements Canadian Immunization Guide Product Monograph		